Search

Displaying results 6421 - 6430 of 10000 in total
  1. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.

  2. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  3. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    [A225691, A225696] This drug is used in the treatment of thrombocytopenia.

  4. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS usin...

  5. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  6. Drug

    Phthalylsulfathiazole

    go.drugbank.com/drugs/DB13248
    Approved

    It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

  7. Drug

    Clevidipine

    go.drugbank.com/drugs/DB04920
    ApprovedInvestigational

    Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

  8. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]

  9. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  10. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.